Cargando…
Less necessity of adjuvant S‐1 treatment in non‐monarchE‐eligible patients
BACKGROUND: In monarchE and Postoperative Therapy with Endocrine and TS‐1 (POTENT) trials, abemaciclib and S‐1 have, respectively, shown to be effective as adjuvant therapies for luminal breast cancer (BC), although whether patients who meet the criteria are at high risk of recurrence compared to no...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315737/ https://www.ncbi.nlm.nih.gov/pubmed/37162105 http://dx.doi.org/10.1002/cam4.6006 |